Autoimmune Hepatitis and PSC Connection

Clinics in Liver Disease

Volumn 12, Issue 1, 2008, Pages 187-202

  Vergani, Diego ^a   Mieli Vergani, Giorgina ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; URSODEOXYCHOLIC ACID;

AGGRESSION; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; GENETICS; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OUTCOME ASSESSMENT; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SEX RATIO; SPECTROSCOPY; TREATMENT RESPONSE;

CHOLANGITIS, SCLEROSING; HEPATITIS, AUTOIMMUNE; HUMANS;

EID: 38549119552     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.11.012     Document Type: Review

References (57)

1. Waldenstrom J. Leber, blutproteine und nahrungseiweiss. Dtsch Z Verdau Staffwechselkr 15 (1950) 113-119
2. Joske R.A., and King W.E. The L.E.-cell phenomenon in active chronic viral hepatitis. Lancet 269 6888 (1955) 477-480
3. Mackay I.R., Taft L.I., and Cowling D.C. Lupoid hepatitis. Lancet 2 (1956) 1323-1326
4. Mackay I.R., Weiden S., and Hasker J. Autoimmune hepatitis. Ann N Y Acad Sci 124 2 (1965) 767-780
5. Reuben A. A sheep in wolf's clothing. Hepatology 38 6 (2003) 1596-1601
6. Zum Buschenfelde K.H. Autoimmune hepatitis: hepatitis sui generis. J Hepatol 38 2 (2003) 130-135
7. Homberg J.C., Abuaf N., Bernard O., et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of autoimmune hepatitis. Hepatology 7 6 (1987) 1333-1339
8. Delbet P. Retrecissement du choledoque: cholecystoduodenostomie. Bull Mem Soc Nat Chir 50 (1924) 1144-1146
9. Miller R. Benign stricture of common bile duct. Ann Surg 86 (1927) 296-303
10. Holubitsky I.B., and McKenzie A.D. Primary sclerosing cholangitis of the extrahepatic bile ducts. Can J Surg 7 (1964) 277-283
11. Warren K.W., Athanassiades S., and Monge J.I. Primary sclerosing cholangitis: a study of forty-two cases. Am J Surg 111 1 (1966) 23-38
12. Johnson P.J., and McFarlane I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology 18 4 (1993) 998-1005
13. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 5 (1999) 929-938
14. Simmonds M.J., and Gough S.C. Genetic insights into disease mechanisms of autoimmunity. Br Med Bull 71 (2004) 93-113
15. Liston A., Lesage S., Gray D.H., et al. Genetic lesions in T-cell tolerance and thresholds for autoimmunity. Immunol Rev 204 (2005) 87-101
16. Vergani D., and Mieli-Vergani G. Autoimmune hepatitis. Autoimmun Rev 2 5 (2003) 241-247
17. Balasubramaniam K., Wiesner R.H., and LaRusso N.F. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. Gastroenterology 95 5 (1988) 1395-1398
18. Wee A., and Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts?. Ann Intern Med 102 5 (1985) 581-587
19. Kaplan M.M. Medical approaches to primary sclerosing cholangitis. Semin Liver Dis 11 1 (1991) 56-63
20. Gregorio G.V., Portmann B., Karani J., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33 3 (2001) 544-553
21. Vergani D., Alvarez F., Bianchi F.B., et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 41 4 (2004) 677-683
22. Tan E.M., Feltkamp T.E., Smolen J.S., et al. Range of antinuclear antibodies in healthy individuals. Arthritis Rheum 40 9 (1997) 1601-1611
23. Abuaf N., Johanet C., Chretien P., et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 16 4 (1992) 892-898
24. Wies I., Brunner S., Henninger J., et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355 9214 (2000) 1510-1515
25. Ma Y., Bogdanos B.P., Williams R., et al. Anti-SLA antibody is a marker of severity of liver damage in patients with autoimmune liver disease. J Hepatol 34 Suppl 1 (2001) 212
26. Czaja A.J., Shums Z., and Norman G.L. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 37 3 (2004) 195-201
27. Vergani D., and Mieli-Vergani G. Hepatic diseases: sclerosing cholangitis. In: Mackay I.R., and Rose N.R. (Eds). The autoimmune diseases. 4th edition (2006), Elsevier Academic Press, Amsterdam 767-777
28. Frenzer A., Fierz W., Rundler E., et al. Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. J Gastroenterol Hepatol 13 9 (1998) 950-954
29. Targan S.R., Landers C., Vidrich A., et al. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. [see comments]. Gastroenterology 108 4 (1995) 1159-1166
30. Zauli D., Ghetti S., Grassi A., et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 25 5 (1997) 1105-1107
31. Terjung B., Spengler U., Sauerbruch T., et al. Atypical p-ANCA in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 119 2 (2000) 310-322
32. Lee Y.M., and Kaplan M.M. Primary sclerosing cholangitis. N Engl J Med 332 14 (1995) 924-933
33. Donaldson P.T. Genetics in autoimmune hepatitis. Semin Liver Dis 22 4 (2002) 353-364
34. Donaldson P.T. Genetics of autoimmune and viral liver diseases; understanding the issues. J Hepatol 41 2 (2004) 327-332
35. Ma Y., Bogdanos D.P., Hussain M.J., et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 130 3 (2006) 868-882
36. Al-Chalabi T., Boccato S., Portmann B.C., et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 45 4 (2006) 575-583
37. Donaldson P.T., and Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 35 8 (2002) 555-564
38. Satsangi J., Chapman R.W., Haldar N., et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 121 1 (2001) 124-130
39. Underhill J., Ma Y., Bogdanos D.P., et al. Different immunogenetic background in autoimmune hepatitis type 1, type and autoimmune sclerosing cholangitis. J Hepatol 36 Suppl 1 (2002) 156A
40. Weaver C.T., Harrington L.E., Mangan P.R., et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 6 (2006) 677-688
41. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13 2 (2007) 139-145
42. Longhi M.S., Ma Y., Bogdanos D.P., et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 41 1 (2004) 31-37
43. Longhi M.S., Ma Y., Mitry R.R., et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 25 1 (2005) 63-71
44. Longhi M.S., Hussain M.J., Mitry R.R., et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 176 7 (2006) 4484-4491
45. Longhi M.S., Hussain M.J., Bogdanos D.P., et al. Cytochrome P450IID6-specific effector CD8 T-cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 46 (2007) 472-484
46. Vierling J.M. Aetiopathogenesis of primary sclerosing cholangitis. In: Manns M.P., Stieihl A., and Wiesner R.H. (Eds). Primary sclerosis cholangitis (1998), Kluwer Academic Publishers, London 9
47. Fausa O., Schrumpf E., and Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 11 1 (1991) 31-39
48. Cangemi J.R., Wiesner R.H., Beaver S.J., et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 96 3 (1989) 790-794
49. Grant A.J., Lalor P.F., Salmi M., et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359 9301 (2002) 150-157
50. Czaja A.J. Treatment of autoimmune hepatitis. Semin Liver Dis 22 4 (2002) 365-378
51. Harnois D.M., and Lindor K.D. Primary sclerosing cholangitis: evolving concepts in diagnosis and treatment. Dig Dis 15 1-2 (1997) 23-41
52. Mitchell S.A., Bansi D.S., Hunt N., et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121 4 (2001) 900-907
53. Harnois D.M., Angulo P., Jorgensen R.A., et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96 5 (2001) 1558-1562
54. Myers R.N., Cooper J.H., and Padis N. Primary sclerosing cholangitis: complete gross and histologic reversal after long-term steroid therapy. Am J Gastroenterol 53 6 (1970) 527-538
55. Javett S.L. Azathioprine in primary sclerosing cholangitis. Lancet 1 7703 (1971) 810
56. el-Shabrawi M., Wilkinson M.L., Portmann B., et al. Primary sclerosing cholangitis in childhood. Gastroenterology 92 5 Pt 1 (1987) 1226-1235
57. Abdalian R., Dhar P., Jhaveri K., et al. Prevalence of primary sclerosing cholangitis in adult patients with primary diagnosis of autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 42 (2005) 208A